Clinical Trial Protocol: Can GLP-1 Drugs Help People with Diabetes Quit Smoking?
A randomized trial will test whether GLP-1 receptor agonists reduce cigarette consumption in type 2 diabetes patients, using brain imaging to explore reward pathway mechanisms.
Quick Facts
What This Study Found
This protocol establishes a rigorous framework to test whether GLP-1RAs reduce smoking in T2DM patients, with fMRI to explore neural reward pathway mechanisms.
Key Numbers
How They Did This
Single-center, parallel-group randomized controlled trial protocol with functional MRI neuroimaging component.
Why This Research Matters
Smoking doubles cardiovascular risk in diabetes. If GLP-1 drugs — already prescribed for blood sugar — also reduce smoking, they could provide dual protection for millions of diabetic smokers.
The Bigger Picture
Growing evidence that GLP-1 drugs reduce addictive behaviors (alcohol, food, possibly drugs) is expanding their potential impact far beyond diabetes and obesity into addiction medicine.
What This Study Doesn't Tell Us
Protocol paper only — no results yet; single-center design; T2DM patients may not represent all smokers.
Questions This Raises
- ?Could GLP-1 drugs become a first-line smoking cessation aid for diabetic patients?
- ?Do the reward pathway effects of GLP-1 drugs extend to other addictions beyond smoking and alcohol?
Trust & Context
- Key Stat:
- GLP-1 + smoking cessation RCT First randomized trial protocol testing GLP-1 effects on nicotine dependence with fMRI
- Evidence Grade:
- Study protocol — no results yet. Describes methodology for a rigorous future trial.
- Study Age:
- Published in 2026, reflecting growing interest in GLP-1 drug effects on addictive behaviors.
- Original Title:
- Effect of glucagon-like peptide-1 receptor agonists on cigarette smoking consumption in type 2 diabetes patients: study protocol of a randomized, parallel -controlled clinical trial.
- Published In:
- Frontiers in clinical diabetes and healthcare, 7, 1665837 (2026)
- Authors:
- Chen, Da, Li, Ziyi(2), Zhou, Chenxia, Li, Ruoxuan, Ji, Xinnan, Feng, Bo, Song, Jun
- Database ID:
- RPEP-14973
Evidence Hierarchy
Frequently Asked Questions
How could a diabetes drug help people quit smoking?
GLP-1 drugs affect the brain's reward system — the same circuits that drive nicotine cravings. By dampening reward-seeking behavior, these drugs may reduce the urge to smoke, similar to how they reduce overeating.
Will this study prove GLP-1 drugs help with smoking?
This is the study protocol — the trial needs to be completed first. But it will provide the first randomized evidence on whether GLP-1 drugs affect smoking in diabetes patients.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14973APA
Chen, Da; Li, Ziyi; Zhou, Chenxia; Li, Ruoxuan; Ji, Xinnan; Feng, Bo; Song, Jun. (2026). Effect of glucagon-like peptide-1 receptor agonists on cigarette smoking consumption in type 2 diabetes patients: study protocol of a randomized, parallel -controlled clinical trial.. Frontiers in clinical diabetes and healthcare, 7, 1665837. https://doi.org/10.3389/fcdhc.2026.1665837
MLA
Chen, Da, et al. "Effect of glucagon-like peptide-1 receptor agonists on cigarette smoking consumption in type 2 diabetes patients: study protocol of a randomized, parallel -controlled clinical trial.." Frontiers in clinical diabetes and healthcare, 2026. https://doi.org/10.3389/fcdhc.2026.1665837
RethinkPeptides
RethinkPeptides Research Database. "Effect of glucagon-like peptide-1 receptor agonists on cigar..." RPEP-14973. Retrieved from https://rethinkpeptides.com/research/chen-2026-effect-of-glucagonlike-peptide1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.